Cancer Biology is the scientific study of the cellular, molecular, genetic, physiological and ecological processes through which normal cells become malignant, proliferate abnormally, interact with surrounding tissues and potentially spread to distant sites. Cancer is not a single disease but a broad group of disorders characterised by abnormal regulation of cell growth, survival, differentiation and tissue organisation. Cancer Biology examines alterations affecting genes, proteins, signalling pathways, cellular metabolism, genome stability and interactions between malignant cells and their surrounding environment.
It also studies how tumours evolve as populations of heterogeneous cells subjected to selection pressures such as immune responses, nutrient limitation and treatment. The field connects molecular biology with pathology, genetics, immunology, developmental biology and clinical medicine. A central concept is that cancer develops through accumulated alterations that disrupt normal controls, although the precise combination and sequence vary among cancers. Understanding these mechanisms supports classification, biomarker development, treatment design and investigation of why tumours behave differently between individuals.
Normal tissues maintain controlled growth through coordinated signals that regulate cell division, differentiation, survival and programmed cell death. Cancer can arise when genetic or epigenetic changes disrupt these controls. Genes involved in growth signalling can become abnormally activated, while genes that normally restrain proliferation or preserve genome integrity can become inactivated. Alterations in DNA repair systems can increase mutation rates and facilitate further evolution.
Some changes are inherited through the germline and increase susceptibility, while many others arise during life in individual cells and are not inherited. Environmental exposures, replication errors, chronic tissue injury and other processes can contribute to the accumulation of alterations. The development of malignancy is therefore generally a multistep process rather than the consequence of a single mutation. Cancer Biology investigates which alterations are causally important, which are consequences of malignant transformation and which may simply be associated passenger changes without a major role in tumour behaviour.
The genome of a tumour is usually heterogeneous because malignant cells continue to acquire genetic and epigenetic alterations as they divide. Different subpopulations within the same tumour can therefore have distinct biological properties, including differences in growth rate, metabolism, immune recognition and treatment sensitivity. Clonal evolution describes the changing composition of these cellular populations as variants with particular advantages expand under relevant selection pressures. Treatment itself can create a strong selection environment, potentially allowing resistant subpopulations to become more prominent.
This does not mean that every detected mutation drives cancer or treatment resistance. Cancer genomic analysis distinguishes driver alterations, which contribute to malignant behaviour, from passenger alterations that accompany tumour evolution without providing a major selective advantage. Tumour heterogeneity complicates diagnosis and treatment because a sample from one region may not represent every cellular population in the tumour. Cancer Biology therefore increasingly studies tumours as dynamic evolving systems rather than uniform masses of identical cells.
Cell signalling is central to Cancer Biology because cells continuously interpret external and internal signals that regulate proliferation, survival and differentiation. Abnormal activation of growth signalling pathways can cause cells to divide when they should remain quiescent, while disruption of death pathways can allow damaged cells to survive. Altered signalling can also influence metabolism, migration, interaction with neighbouring cells and response to stress. Developmental pathways that normally control tissue patterning can become dysregulated in malignancy.
Transcriptional programmes can change the identity and behaviour of cells, while epigenetic modifications can alter gene expression without changing the underlying DNA sequence. The same signalling alteration can have different consequences depending on cell type and tissue context because cellular networks are interconnected and subject to feedback. Cancer Biology therefore does not interpret individual molecules in isolation but examines networks of interacting pathways and the consequences of perturbing those networks.
The tumour microenvironment consists of malignant cells together with surrounding non malignant cells, extracellular structures, blood vessels, immune cells and signalling molecules. Cancer cells can modify this environment to support growth, invasion and survival. Interactions with immune cells can produce either anti tumour responses or conditions that suppress effective immune activity. Stromal cells and extracellular matrix components can influence tissue architecture, migration and treatment penetration. Tumours can also alter blood vessel formation and local nutrient availability.
These interactions demonstrate that malignant behaviour is not determined solely by the genome of cancer cells. Tissue context can affect whether particular alterations produce a malignant phenotype and can influence how tumours respond to treatment. The study of these interactions is particularly important for understanding why therapies that target cancer cells directly may fail when the surrounding environment provides alternative survival signals or limits drug delivery.
Metabolism is frequently altered in cancer because proliferating cells require energy, molecular building blocks and systems for managing oxidative and other forms of cellular stress. Some tumours increase glucose uptake and redirect metabolic intermediates toward biosynthetic processes even when oxygen is available, although cancer metabolism is diverse and context dependent rather than governed by one universal pattern. Altered mitochondrial activity, lipid metabolism, amino acid metabolism and redox regulation can also contribute to malignant behaviour.
Metabolic adaptation can help tumour cells survive fluctuating nutrient and oxygen availability within the tumour environment. These metabolic features can sometimes be exploited for imaging or treatment, but metabolic pathways are also present in normal cells, creating challenges for therapeutic selectivity. Cancer Biology therefore investigates metabolism both as a consequence of malignant transformation and as a potential vulnerability. Understanding metabolism requires integrating biochemical pathways with genetics, tissue physiology and environmental conditions within tumours.
Cancer development involves local invasion and, in some cases, dissemination to distant organs. Malignant cells can alter adhesion, interact with extracellular structures, migrate through tissues and enter blood or lymphatic vessels. Successful establishment at a distant site requires survival during transport, exit from circulation, adaptation to the new tissue environment and growth within that environment. This process is selective and inefficient, meaning that the presence of malignant cells in circulation does not automatically imply successful metastatic growth.
Different cancers have characteristic patterns of organ involvement, influenced by blood flow, tissue compatibility, molecular interactions and ecological conditions. Tumour cells can also remain dormant for periods before becoming clinically detectable. Cancer Biology studies these processes to understand why some cells disseminate while others do not and why particular treatments may control the primary tumour without preventing later recurrence.
Cancer Biology has transformed diagnosis and treatment by identifying molecular alterations that can serve as biomarkers or therapeutic targets. Biomarkers may provide information about tumour classification, prognosis, likely treatment response or disease monitoring, but their interpretation depends on validation and clinical context. Targeted therapies attempt to exploit specific molecular dependencies, while immunological approaches seek to enhance or redirect immune recognition of malignant cells.
Conventional treatments can act through broad mechanisms affecting rapidly dividing cells, but resistance can arise through genetic evolution, pathway adaptation, altered drug transport, changes in cell state or protective microenvironmental interactions. A common misconception is that identifying a mutation automatically identifies an effective treatment, because a molecular alteration may not be causally important, targetable or present throughout the tumour. The wider significance of Cancer Biology lies in explaining malignant transformation as an evolving biological process and providing mechanistic foundations for more precise classification, prevention, diagnosis, treatment and monitoring of cancer.
